Vasomedical Announces Strong Revenue Growth for the Three Months Ended March 31, 2012

Advanced Heart Disease Patient Regains Lost Energy, Attends 50-Year Class Reunion After Receiving EECP® Therapy at Heart House in Washington Township

Vasomedical Successfully Exhibited at the 61st Annual Scientific Sessions of the American College of Cardiology

Vasomedical Announces Record Operating Income of $5.2 Million and 169% Increase in Revenue for the Seven Months Ended December 31, 2011

Florida Cardiologist Tells Angina Patients, “Don’t Give Up Hope: Non-Invasive EECP® Therapy Can Relieve Chest Pain when Stents and Bypasses Do Not”

More >>

January 23, 2012

New Indian Health Magazine Features EECP® Therapy In Its Cover Story 

February Edition Of Health Café Features EECP®

WESTBURY, N.Y.  (February 3, 2012) – Vasomedical, Inc. (“Vasomedical”) (OTC: VASO.PK), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, announced today that Health Café, the first magazine in India dedicated solely to health issues, ran its cover story on EECP® therapy as “EECP Huge Hope for Heart Patients”. The article touches on the many areas of cardiovascular disease including discussions on risk factors and the evolution of the disease and its possible treatments. Second only to the United States, the adoption and acceptance of EECP® therapy in India, has grown significantly over the last ten years. With more than 85 EECP® treatment centers, including over 20 of the top hospitals in India, the availability of EECP® therapy for patients all over the country has been established.

In addition to successfully and inexpensively treating coronary disease many physicians in India, aware of the recent scientific evidence demonstrating the effectiveness of EECP® therapy in improving vascular health look to the expansion of clinical use in such areas as hypertension, diabetes, kidney disease, erectile dysfunction, stroke, Parkinson’s disease and Alzheimers disease and retinopathy. The article highlights key opinion leaders support of and experience with EECP® therapy as well as describes its research uncovering the use of EECP® therapy by a number of well known celebrities for a myriad of reasons.

The article also reviews the recent addition and combination of EECP® therapy to the Ayurvedic medicine provided at the Art of Living International Center in Bangalore. A quote of His Holiness Sri Sri Ravi Shankar, “EECP – the first allopathic treatment that gives improvement to cardiac patients in a natural way” appears on the cover of the magazine under His Holiness’ picture.  

Dr. Ramasamy, International Medical Director for the International EECP® Therapists Association refers to EECP® as the “new wonder in the treatment of heart disease.” “It’s a revolution in the treatment of heart disease……..It is totally non-invasive, painless therapy that needs no hospitalization and involves no surgery, needles or injections. ”, further stated Dr. Ramasamy.  

To view the article in its entirety click here: Health Cafe Magazine February 2012

Vasomedical, Inc. is engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of cardiovascular diseases and is currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. The Company also provides other noninvasive medical equipment including Holter monitors and ambulatory blood pressure monitors.

Vaso Diagnostics d/b/a VasoHealthcare, a wholly owned subsidiary of Vasomedical, Inc., is a professional sales representation organization offering vendors of medical devices an alternative third party sales channel. Through an agreement with GE Healthcare, it is currently engaged as an exclusive sales representative for certain GE Healthcare products.

Additional information is available on the Company's website at www.vasomedical.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.